University of Kansas Medical Center Goes All Out in Research Contributing to Beating COVID-19 and Exiting the Pandemic

University of Kansas Medical Center (KUMC) joined the ACTIV-2 clinical trial recently, targeting those patients diagnosed with mild COVID-19 symptoms in a quest to determine how the advanced monoclonal antibody-based product developed by Eli Lilly, LY-COV555, can help...

Lilly’s Monoclonal Antibody Produces Positive Data, Company Gears up for Further Review & Inks Production Deal with Amgen

TrialSite News reported on Aug 22 that a South Texas trial site location reported growing confidence in a SARS-CoV-2 neutralizing antibody-based investigational product developed by Eli Lilly (Lilly) called LY-CoV555. Developed with the help of powerful discovery...

Pin It on Pinterest